title: [Response to treatment of patients abusing the "dappou drug" who participated in a group relapse prevention program: a comparison with patients abusing methamphetamine].
abstract: In this study, we compared the efficacy of a group relapse prevention program using the cognitive behavioral therapy-based workbook, Serigaya Methamphetamine Relapse Prevention Program (SMARPP), between patients abusing the so-called "dappou drugs" (designer drug in Japan, and those abusing methamphetamine (MAP). Both groups participated in the SMARPP at the Center Hospital, National Center of Neurology and Psychiatry. Results showed that, no significant differences were found in the rates of participation in the program or self-reported frequency of drug or alcohol use between the patients abusing "dappou drugs" or MAP. However, patients using "dappou drugs" reported no significant increase in their confidence in their ability to resist the temptation to use drugs on the self- report drug abuse scales after the SMARPP intervention, while patients abusing MAP reported a significant positive difference in their ability to resist temptation. In addition, insight into substance abuse problems and motivation to participate in further treatment slightly declined in those using "dappou drugs," while there was a significant increase reported by the patients using MAP. These results suggested that the SMARPP might not be as effective for patients abusing "dappou drugs" as for those abusing MAP. The development of a relapse prevention program specifically designed for patients abusing "dappou drugs" is required.
authors.forename: Emi
authors.initials: E
authors.lastname: Hikitsuchi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Wada
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tanibuchi
authors.forename: Ayumi
authors.initials: A
authors.lastname: Takano
authors.forename: Fumi
authors.initials: F
authors.lastname: Imamura
authors.forename: Hiraku
authors.initials: H
authors.lastname: Kawachi
authors.forename: Asako
authors.initials: A
authors.lastname: Wakabayashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Kato
mesh_terms: D000328:Adult; D015928:Cognitive Behavioral Therapy; D003156:Community Mental Health Services; D015198:Designer Drugs; D059026:Diagnostic Self Evaluation; D005260:Female; D006778:Hospitals, Psychiatric; D006779:Hospitals, Public; D006801:Humans; D007564:Japan; D008297:Male; D008694:Methamphetamine / Q000506:poisoning*; D009042:Motivation; D010358:Patient Participation; D011615:Psychotherapy, Group; D012008:Recurrence; D055502:Secondary Prevention; D012720:Severity of Illness Index; D019966:Substance-Related Disorders / Q000517:prevention & control* / Q000523:psychology*; D016896:Treatment Outcome
chemical_list: D015198:Designer Drugs; D008694:Methamphetamine